Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$3.58 +1.7%	$2.14	$0.40 ▼ $5.48	$59.78M	0.37	357,103 shs	407,681 shs
ADVM Adverum Biotechnologies	$2.84 +2.9%	$2.42	$1.78 ▼ $10.14	$57.66M	0.7	253,111 shs	138,099 shs
NEUP Neuphoria Therapeutics	$7.49 +0.4%	$6.62	$2.12 ▼ $12.55	$14.02M	0.5	33,719 shs	29,292 shs
NRXP NRx Pharmaceuticals	$3.03 +0.7%	$3.01	$1.10 ▼ $6.01	$52.04M	1.59	422,477 shs	137,432 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-1.40%	-24.79%	+80.51%	+311.70%	+345.51%
ADVM Adverum Biotechnologies	+4.94%	+8.66%	+11.74%	-5.80%	-69.06%
NEUP Neuphoria Therapeutics	-1.32%	0.00%	+11.34%	+45.14%	+745,999,900.00%
NRXP NRx Pharmaceuticals	-3.22%	-10.42%	-13.51%	+55.96%	+20.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVC ABVC BioPharma	0.3948 of 5 stars	0.0	3.0	0.0	2.4	0.8	0.0
ADVM Adverum Biotechnologies	4.4217 of 5 stars	3.4	4.0	4.8	1.6	2.5	0.6
NEUP Neuphoria Therapeutics	2.2517 of 5 stars	3.5	0.0	0.0	3.8	0.0	0.6
NRXP NRx Pharmaceuticals	2.7932 of 5 stars	3.6	4.0	0.0	2.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	0.00	N/A	N/A	N/A
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	738.03% Upside
NEUP Neuphoria Therapeutics	3.00	Buy	$21.00	180.37% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	840.59% Upside

Current Analyst Ratings Breakdown

Latest NEUP, ABVC, ADVM, and NRXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
5/16/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
4/17/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $33.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	$510K	119.19	N/A	N/A	$0.06 per share	59.67
ADVM Adverum Biotechnologies	$1M	59.33	N/A	N/A	$3.40 per share	0.84
NEUP Neuphoria Therapeutics	$10K	1,408.12	N/A	N/A	$15.85 per share	0.47
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$4.90M	-$0.13	N/A	∞	N/A	-963.46%	-29.62%	-14.08%	8/13/2025 (Estimated)
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
NEUP Neuphoria Therapeutics	-$15.49M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/29/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$25.13M	-$2.01	N/A	N/A	N/A	N/A	N/A	-355.00%	8/13/2025 (Estimated)

Latest NEUP, ABVC, ADVM, and NRXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	NRXP NRx Pharmaceuticals	-$0.31	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ADVM Adverum Biotechnologies	-$2.24	N/A	N/A	N/A	N/A	N/A
5/20/2025	Q3 2025	NEUP Neuphoria Therapeutics	-$0.47	$6.55	+$7.02	$6.55	N/A	$15.00 million
5/15/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	-$0.34	+$0.06	-$0.34	$1.14 million	$1.14 million
4/30/2025	Q4 2024	ABVC ABVC BioPharma	N/A	-$0.06	N/A	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.22	0.22
ADVM Adverum Biotechnologies	N/A	3.57	3.57
NEUP Neuphoria Therapeutics	N/A	11.01	11.01
NRXP NRx Pharmaceuticals	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
ADVM Adverum Biotechnologies	48.17%
NEUP Neuphoria Therapeutics	15.90%
NRXP NRx Pharmaceuticals	4.27%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	17.10%
ADVM Adverum Biotechnologies	6.00%
NEUP Neuphoria Therapeutics	0.69%
NRXP NRx Pharmaceuticals	19.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	16.98 million	14.08 million	Not Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
NEUP Neuphoria Therapeutics	N/A	1.88 million	1.87 million	N/A
NRXP NRx Pharmaceuticals	2	17.29 million	14.00 million	Optionable

NEUP, ABVC, ADVM, and NRXP Headlines

Recent News About These Companies

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Positioning at the Forefront of Next-Gen Treatment

July 17 at 3:20 AM | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $28.50 Average Target Price from Analysts

July 14 at 2:41 AM | americanbankingnews.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Rating of "Buy" by Brokerages

July 11, 2025 | marketbeat.com

NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

July 9, 2025 | financial-news.co.uk

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

July 9, 2025 | finance.yahoo.com

NRx Pharmaceuticals (NASDAQ:NRXP) Stock Price Down 0.3% - Here's What Happened

July 8, 2025 | marketbeat.com

NRX Pharmaceuticals Inc Ordinary Shares NRXP - Morningstar

July 3, 2025 | morningstar.comM

NRx Pharmaceuticals (NASDAQ: NRXP) Applies for FDA Commissioner's National Priority Voucher for IV Ketamine NRX-100 - Benzinga

July 2, 2025 | benzinga.com

NRx Pharmaceuticals (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

June 30, 2025 | financial-news.co.uk

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Applies for FDA Commissioner's National Priority Voucher for IV Ketamine NRX-100

June 30, 2025 | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NRXP) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional ...

June 27, 2025 | nasdaq.com

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic

June 27, 2025 | finance.yahoo.com

NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic

June 26, 2025 | financial-news.co.uk

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

June 26, 2025 | prnewswire.com

NRX Pharmaceuticals Inc News (NRXP) - Investing.com

June 24, 2025 | investing.com

IBN Initiates Coverage of NRx Pharmaceuticals Inc.

June 24, 2025 | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

June 23, 2025 | prnewswire.com

NRx Pharmaceuticals (NASDAQ:NRXP) Receives "Buy" Rating from D. Boral Capital

June 20, 2025 | marketbeat.com

IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

June 17, 2025 | finance.yahoo.com

NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

June 16, 2025 | financial-news.co.uk

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEUP, ABVC, ADVM, and NRXP Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$3.58 +0.06 (+1.70%)

Closing price 04:00 PM Eastern

Extended Trading

$3.47 -0.11 (-3.07%)

As of 07:42 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Adverum Biotechnologies NASDAQ:ADVM

$2.84 +0.08 (+2.90%)

Closing price 04:00 PM Eastern

Extended Trading

$2.84 +0.01 (+0.18%)

As of 04:21 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Neuphoria Therapeutics NASDAQ:NEUP

$7.49 +0.03 (+0.40%)

As of 03:42 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

NRx Pharmaceuticals NASDAQ:NRXP

$3.03 +0.02 (+0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$3.05 +0.02 (+0.66%)

As of 07:50 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time